Previous 10 | Next 10 |
Webinar Wednesdays is planned to be held on the last Wednesday of each month - starting on Wednesday, April 24th (at 1PM Eastern) with the first webinar on the increasing prevalence of non-small cell lung cancer in never smokers and how drug candidate LP-300 and the Harmonic Clinical Tr...
Approximately 33% of all non-small cell lung cancer patients in East Asia are never smokers – a growing and unaddressed patient population. Dr. Yashushi Goto a leading lung cancer clinician-scientist at the renowned National Cancer Center of Japan will be a lead investigator. ...
2024-04-10 08:45:32 ET Palm Beach, FL – April 10, 2024 – FN Media Group News Commentary – With the increase in life expectancy, people need more medical help and care. AI-enabled technologies can help people to live healthier and longer lives. Artificial Int...
2024-03-28 09:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
PALM BEACH, Fla., March 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The use of Artificial Intelligence (AI) in medical diagnosis is taking broad strides in recent years and is projected to continue at a high rate in coming years. A report from MarketsAndMarkets o...
2024-03-19 12:48:26 ET More on Mid-day movers & stocks. Ontrak Health announces continuing expansion with Sentara Health Sarcos Technology and Robotics says co-founder Ben Wolff to become CEO Financial information for Aptorum Group Seeking Alpha’s ...
2024-03-19 10:00:51 ET More on Health Care Select Sector SPDR XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming Johnson & Johnson, Boston...
2024-03-18 23:14:02 ET Lantern Pharma Inc. (LTRN) Q4 2023 Earnings Conference Call March 18, 2024, 04:30 PM ET Company Participants Panna Sharma - President and Chief Executive Officer David Margrave - Chief Financial Officer Conference Call Participants ...
2024-03-18 16:08:33 ET More on Lantern Pharma Seeking Alpha’s Quant Rating on Lantern Pharma Historical earnings data for Lantern Pharma Financial information for Lantern Pharma Read the full article on Seeking Alpha For further details see: ...
Multiple clinical trials across three AI-guided drug candidates are active with first expected data and readouts for LP-184 in the second half of 2024; with additional next-generation drug development programs approaching IND studies. Dosed initial patients in both Phase 1 clinical trials for...
News, Short Squeeze, Breakout and More Instantly...
Lantern Pharma (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging artificial intelligence (AI) and machine learning to transform the cost, pace, and timeline of oncology drug discovery and development, today announced a significant advancement towards the development of a diagn...
LP-284 is currently in a Phase 1 clinical trial, having been developed with guidance from Lantern’s AI platform, RADR ® , as a potential therapy for relapsed or refractory non-Hodgkin’s lymphoma and certain genomically defined sarcomas. LP-284 is the third molecule brou...
Active clinical trials across three AI-guided drug candidates with initial data and clinical readouts for LP-184 on-track for the second half of 2024. Obtained regulatory allowance to begin Phase 2 Harmonic™ clinical trial enrollment in Japan and Taiwan where approximately 30-35+% ...